Literature DB >> 34265471

Supramolecular micelles as multifunctional theranostic agents for synergistic photodynamic therapy and hypoxia-activated chemotherapy.

Xiaobei Huang1, Tunan Chen2, Ning Mu2, Hou Wang Lam3, Chen Sun4, Ludan Yue4, Qian Cheng4, Cheng Gao4, Zhen Yuan5, Ruibing Wang6.   

Abstract

Photodynamic therapy (PDT), where a photosensitizer (under light irradiation) converts molecular oxygen to singlet oxygen to elicit programmed cell death, is a promising cancer treatment modality with a high temporal and spatial resolution. However, only limited cancer treatment efficacy has been achieved in clinical PDT due to the hypoxic conditions of solid tumor microenvironment that limits the generation of singlet oxygen, and PDT process often leads to even more hypoxic microenvironment due to the consumption of oxygens during therapy. Herein, we designed novel supramolecular micelles to co-deliver photosensitizer and hypoxia-responsive prodrug to improve the overall therapeutic efficacy. The supramolecular micelles (CPC) were derived from a polyethylene glycol (PEG) system dually tagged with hydrophilic cucurbit[7]uril (CB[7]) and hydrophobic Chlorin e6 (Ce6), respectively on each end, for synergistic antitumor therapy via PDT of Ce6 and chemotherapy of a hypoxia-responsive prodrug, banoxantrone (AQ4N), loaded into the cavity of CB[7]. In addition, CPC was further modularly functionalized by folate (FA) via strong host-guest interaction between folate-amantadine (FA-ADA) and CB[7] to produce a novel nanoplatform, AQ4N@CPC-FA, for targeted delivery. AQ4N@CPC-FA exhibited enhanced cellular uptake, negligible cytotoxicity and good biocompatibility, and improved intracellular reactive oxygen species (ROS) generation efficiency. More importantly, in vivo evaluation of AQ4N@CPC-FA revealed a synergistic antitumor efficacy between PDT of Ce6 and hypoxia-activated chemotherapy of AQ4N (that can be converted to chemotherapeutic AQ4 for tumor chemotherapy in response to the strengthened hypoxic tumor microenvironment during PDT treatment). This study not only provides a new nanoplatform for synergistic photodynamic-chemotherapeutic treatment, but also offers important new insights to design and development of multifunctional supramolecular drug delivery system. STATEMENT OF SIGNIFICANCE: Photodynamic therapy (PDT) has exhibited a variety of advantages for cancer phototherapy as compared to traditional chemotherapy. However, the unsatisfactory therapeutic efficacy by PDT alone as a result of the enhanced tumor hypoxia during PDT has limited its clinical application. Herein, we designed multifunctional supramolecular micelles to co-deliver photosensitizer and hypoxia-responsive prodrug to improve the overall therapeutic efficacy. The supramolecular micelles are biocompatible and possess strong red absorption, controlled drug release profile, and ultimately enhanced therapeutic outcome via PDT-chemotherapy. This study not only provides a new nanoplatform for synergistic photodynamic-chemotherapeutic treatment of cancer, but also offers important new insights to design and development of multifunctional supramolecular drug delivery tool for multi-modality cancer therapy.
Copyright © 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Controlled drug release; Hypoxia-activated prodrug; Photodynamic-chemotherapeutic therapy; Supramolecular; Targeted drug delivery

Year:  2021        PMID: 34265471     DOI: 10.1016/j.actbio.2021.07.014

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  6 in total

1.  A host-guest strategy for converting the photodynamic agents from a singlet oxygen generator to a superoxide radical generator.

Authors:  Kun-Xu Teng; Li-Ya Niu; Qing-Zheng Yang
Journal:  Chem Sci       Date:  2022-04-23       Impact factor: 9.969

2.  Fibroblast activation protein α activatable theranostic pro-photosensitizer for accurate tumor imaging and highly-specific photodynamic therapy.

Authors:  Yong Luo; Zishan Zeng; Ting Shan; Xiaoyu Xu; Jie Chen; Yuanfeng He; Tao Zhang; Zeqian Huang; Guihong Chai; Yanjuan Huang; Yanfang Zhao; Chunshun Zhao
Journal:  Theranostics       Date:  2022-05-01       Impact factor: 11.600

Review 3.  Recent Progress of Metal-Organic Framework-Based Photodynamic Therapy for Cancer Treatment.

Authors:  Yuyun Ye; Yifan Zhao; Yong Sun; Jie Cao
Journal:  Int J Nanomedicine       Date:  2022-05-23

4.  Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer.

Authors:  Vidhi M Shah; Craig Dorrell; Adel Al-Fatease; Brittany L Allen-Petersen; Yeonhee Woo; Yuliya Bortnyak; Rohi Gheewala; Brett C Sheppard; Rosalie C Sears; Adam Wg Alani
Journal:  Pharmaceutics       Date:  2022-03-26       Impact factor: 6.525

Review 5.  Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.

Authors:  Hailong Tian; Tingting Zhang; Siyuan Qin; Zhao Huang; Li Zhou; Jiayan Shi; Edouard C Nice; Na Xie; Canhua Huang; Zhisen Shen
Journal:  J Hematol Oncol       Date:  2022-09-12       Impact factor: 23.168

Review 6.  Advanced Peptide Nanomedicines for Bladder Cancer Theranostics.

Authors:  Sheng Zeng; Xiaodi Feng; Shaoqiang Xing; Zhaoliang Xu; Zhizhao Miao; Qian Liu
Journal:  Front Chem       Date:  2022-08-05       Impact factor: 5.545

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.